Your browser doesn't support javascript.
loading
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Sydes, M R; Spears, M R; Mason, M D; Clarke, N W; Dearnaley, D P; de Bono, J S; Attard, G; Chowdhury, S; Cross, W; Gillessen, S; Malik, Z I; Jones, R; Parker, C C; Ritchie, A W S; Russell, J M; Millman, R; Matheson, D; Amos, C; Gilson, C; Birtle, A; Brock, S; Capaldi, L; Chakraborti, P; Choudhury, A; Evans, L; Ford, D; Gale, J; Gibbs, S; Gilbert, D C; Hughes, R; McLaren, D; Lester, J F; Nikapota, A; O'Sullivan, J; Parikh, O; Peedell, C; Protheroe, A; Rudman, S M; Shaffer, R; Sheehan, D; Simms, M; Srihari, N; Strebel, R; Sundar, S; Tolan, S; Tsang, D; Varughese, M; Wagstaff, J; Parmar, M K B; James, N D.
Affiliation
  • Sydes MR; MRC Clinical Trials Unit at UCL, London. Electronic address: mrcctu.stampede-publications@ucl.ac.uk.
  • Spears MR; MRC Clinical Trials Unit at UCL, London.
  • Mason MD; Cardiff University, Cardiff.
  • Clarke NW; Christie and Royal Salford Hospital, Manchester.
  • Dearnaley DP; Institute of Cancer Research, Sutton.
  • de Bono JS; Institute of Cancer Research, Sutton.
  • Attard G; UCL Cancer Institute, University College London, London.
  • Chowdhury S; Guy's & St Thomas NHS, Foundation Trust, London.
  • Cross W; St James University Hospital, Leeds, UK.
  • Gillessen S; Division of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen; University of Bern, Bern; Swiss Group for Cancer Clinical Research (SAKK), Bern, Switzerland.
  • Malik ZI; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool.
  • Jones R; Institute of Cancer Sciences, University of Glasgow, Glasgow; Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow.
  • Parker CC; Institute of Cancer Research, Sutton; Royal Marsden Hospital, Sutton.
  • Ritchie AWS; MRC Clinical Trials Unit at UCL, London.
  • Russell JM; Institute of Cancer Sciences, University of Glasgow, Glasgow; Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow.
  • Millman R; MRC Clinical Trials Unit at UCL, London.
  • Matheson D; Faculty of Education, Health and Wellbeing, University of Wolverhampton, Wolverhampton.
  • Amos C; MRC Clinical Trials Unit at UCL, London.
  • Gilson C; MRC Clinical Trials Unit at UCL, London.
  • Birtle A; Rosemere Cancer Centre, Royal Preston Hospital, Preston.
  • Brock S; Dorset Cancer Centre, Poole Hospital, Poole.
  • Capaldi L; Worcestershire Acute Hospitals NHS Trust, Worcester.
  • Chakraborti P; Royal Derby Hospital, Derby.
  • Choudhury A; Division of Cancer Sciences, University of Manchester, Manchester; Manchester Academic Health Science Centre, Manchester; Christie Hospital NHS Foundation Trust, Manchester.
  • Evans L; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield.
  • Ford D; City Hospital, Cancer Centre at Queen Elizabeth Hospital, Birmingham.
  • Gale J; Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth.
  • Gibbs S; Queen's Hospital, Romford.
  • Gilbert DC; Sussex Cancer Centre, Royal Sussex County Hospital, Brighton.
  • Hughes R; Mount Vernon Group, Mount Vernon Hospital, Middlesex.
  • McLaren D; Western General Hospital, Edinburgh.
  • Lester JF; Velindre Cancer Centre, Cardiff.
  • Nikapota A; Sussex Cancer Centre, Brighton.
  • O'Sullivan J; Centre for Cancer Research and Cell Biology, Queens University Belfast, Belfast; Belfast City Hospital, Belfast.
  • Parikh O; Lancashire Teaching Hospitals NHS Trust, Preston.
  • Peedell C; Department of Oncology & Radiotherapy, South Tees NHS Trust, Middlesbrough.
  • Protheroe A; Oxford University Hospitals NHS Foundation Trust.
  • Rudman SM; Guy's & St Thomas NHS, Foundation Trust, London.
  • Shaffer R; Department of Oncology, Royal Surrey County Hospital, Guildford.
  • Sheehan D; Royal Devon and Exeter Hospital, Exeter.
  • Simms M; Hull & East Yorkshire Hospitals NHS Trust, Hull.
  • Srihari N; Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury, UK.
  • Strebel R; Kantonsspital Graubünden, Chur; Swiss Group for Cancer Clinical Research (SAKK), Bern, Switzerland.
  • Sundar S; Department of Oncology, Nottingham, University Hospitals NHS Trust, Nottingham.
  • Tolan S; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool.
  • Tsang D; Southend Hospital, Southend-on-Sea.
  • Varughese M; Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust.
  • Wagstaff J; Swansea University College of Medicine, Swansea.
  • Parmar MKB; MRC Clinical Trials Unit at UCL, London. Electronic address: mrcctu.stampede-publications@ucl.ac.uk.
  • James ND; Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, UK.
Ann Oncol ; 29(5): 1235-1248, 2018 05 01.
Article in En | MEDLINE | ID: mdl-29529169
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Abiraterone Acetate / Docetaxel / Androgen Antagonists Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Humans / Male Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Abiraterone Acetate / Docetaxel / Androgen Antagonists Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Humans / Male Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2018 Type: Article